![Parisa Zamiri](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Parisa Zamiri is currently the Chief Medical Officer at Opthea Ltd. She previously held positions as the Director-Pre-Clinical Sciences at Arsenal Medical, Inc. from 2007 to 2011, the Chief Medical Officer at Graybug Vision, Inc. from 2020 to 2023, and the VP & Global Head-Clinical Development at Novartis AG from 2012 to 2020.
She also served as the Chief Medical Officer at CalciMedica, Inc. and Complement Therapeutics Ltd. Dr. Zamiri holds a doctorate degree from University College London and a graduate degree from King's College London.
Eerdere bekende functies van Parisa Zamiri
| Bedrijven | Functie | Einde |
|---|---|---|
| CERYVYN THERAPEUTICS LIMITED | Hoofd Techniek/Wetenschap/O&O | 15-07-2025 |
| CALCIMEDICA, INC. | Hoofd Techniek/Wetenschap/O&O | 28-02-2023 |
| CALCIMEDICA, INC. | Hoofd Techniek/Wetenschap/O&O | 28-02-2023 |
| NOVARTIS AG | Corporate Officer/Principal | 01-06-2020 |
Arsenal Medical, Inc.
 Arsenal Medical, Inc. Medical SpecialtiesHealth Technology Develops biomaterials provides local therapy for important medical conditions across therapeutic areas | Corporate Officer/Principal | 01-11-2011 |
Opleiding van Parisa Zamiri
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
52
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Arsenal Medical, Inc.
Arsenal Medical, Inc. Medical SpecialtiesHealth Technology Develops biomaterials provides local therapy for important medical conditions across therapeutic areas | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, which focuses on developing transformative medicines for the treatment of chronic diseases of retina and optic nerve | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Opthea Ltd.
 Opthea Ltd. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for treatment retinal diseases | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops complement medicines | Health Technology |
CalciMedica, Inc.
 CalciMedica, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Kies MarketScreener 
